STOCK TITAN

[Form 3] Neuphoria Therapeutics Inc. Initial Statement of Beneficial Ownership

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
3

Neuphoria Therapeutics Inc. (NEUP) received an initial ownership report on Form 3. The filing lists “Director” as the relationship to the issuer and indicates the form was filed by more than one reporting person. The event date is 10/21/2025.

The report shows 236,218 shares of common stock beneficially owned on an indirect basis, held by Lynx1 Master Fund LP. The filing explains that Lynx1 Capital Management LP serves as investment manager to the fund and Weston Nichols is the sole member of the fund manager’s general partner. Each reporting person disclaims beneficial ownership except to the extent of any pecuniary interest.

Neuphoria Therapeutics Inc. (NEUP) ha ricevuto un report iniziale di proprietà su Modulo 3. La comunicazione elenca “Director” come relazione con l'emittente e indica che il modulo è stato presentato da più di una persona informante. La data dell'evento è 21/10/2025.

Il report mostra 236.218 azioni ordinarie di proprietà beneficiaria in modo indiretto, detenute da Lynx1 Master Fund LP. La presentazione spiega che Lynx1 Capital Management LP funge da gestore degli investimenti del fondo e Weston Nichols è l'unico socio accomandatario del gestore del fondo. Ciascun reporting person dichiara di non detenere proprietà beneficiaria salvo per l'eventuale interesse pecuniario.

Neuphoria Therapeutics Inc. (NEUP) recibió un informe inicial de propiedad en el Formulario 3. El registro indica “Director” como la relación con el emisor y señala que el formulario fue presentado por más de una persona informante. La fecha del evento es 21/10/2025.

El informe muestra 236,218 acciones ordinarias de propiedad beneficiaria en una base indirecta, mantenidas por Lynx1 Master Fund LP. La presentación explica que Lynx1 Capital Management LP actúa como administrador de inversiones del fondo y Weston Nichols es el único miembro del socio general del administrador del fondo. Cada persona informante rechaza la propiedad beneficiaria excepto en la medida de cualquier interés pecuniario.

Neuphoria Therapeutics Inc. (NEUP)는 Form 3에서 초기 소유권 보고를 받았습니다. 제출서는 발행자와의 관계를 “이사”로 기재하고 보고자가 둘 이상임을 나타냅니다. 이벤트 날짜는 2025년 10월 21일입니다.

보고서는 236,218주의 일반 주식간접적인 방식으로 유익하게 소유되었다고 표시되며, Lynx1 Master Fund LP가 보유합니다. 제출서는 Lynx1 Capital Management LP가 펀드의 투자관리자로 기능하며 Weston Nichols가 펀드 매니저의 일반 파트너의 유일한 구성원임을 설명합니다. 각 보고자는 금전적 이해관계의 범위에 한해만 유익한 소유권을 포기합니다.

Neuphoria Therapeutics Inc. (NEUP) a reçu un premier rapport de propriété sur le formulaire 3. Le dépôt indique « Directeur » comme relation avec l'émetteur et indique que le formulaire a été déposé par plus d'une personne déclarant. La date de l'événement est le 21/10/2025.

Le rapport indique 236 218 actions ordinaires détenues de manière indirecte par Lynx1 Master Fund LP. Le dépôt explique que Lynx1 Capital Management LP agit en tant que gestionnaire d'investissements du fonds et Weston Nichols est le seul membre du partenaire général du gestionnaire. Chaque personne déclarant décline la propriété bénéficiaire à l'exception de tout intérêt pécuniaire.

Neuphoria Therapeutics Inc. (NEUP) erhielt einen ersten Eigentumsnachweis auf Formular 3. Die Einreichung führt „Director“ als Beziehung zum Emittenten auf und gibt an, dass das Formular von mehr als einer meldepflichtigen Person eingereicht wurde. Das Ereignisdatum ist 2025-10-21.

Der Bericht zeigt 236.218 Stammaktien mit wohltuender Eigentümerschaft auf indirekter Basis, gehalten von Lynx1 Master Fund LP. Die Einreichung erklärt, dass Lynx1 Capital Management LP als Investmentmanager des Fonds fungiert und Weston Nichols der einzige Mitglied des General Partners des Fondsmanagers ist. Jede meldepflichtige Person lehnt die wirtschaftliche Eigentümerschaft ab, außer im Hinblick auf eventuelle finanzielle Interessen.

Neuphoria Therapeutics Inc. (NEUP) تلقّت تقرير ملكية ابتدائي على النموذج 3. يذكر الملف العلاقة مع المصدر بأنها “مدير” ويشير إلى أن النموذج قدمه أكثر من شخص تقرير. تاريخ الحدث هو 21/10/2025.

يظهر التقرير 236,218 سهماً عادياً يملكها بطريقة غير مباشرة، مملوكة من قبل Lynx1 Master Fund LP. يوضح الملف أن Lynx1 Capital Management LP يعمل كمدير استثمار لصندوق الاستثمار وأن Weston Nichols هو العضو الوحيد في الشريك العام لمدير الصندوق. كل شخص تقرير ينفي الملكية المفيدة باستثناء أي مصلحة مالية.

Neuphoria Therapeutics Inc. (NEUP) 收到了 Form 3 的初始所有权报告。该申报把与发行人之关系标注为“董事”,并指出该表由不止一名申报人提交。事件日期为 2025/10/21

该报告显示以间接方式实际拥有的236,218 股普通股,由Lynx1 Master Fund LP持有。申报说明 Lynx1 Capital Management LP 作为该基金的投资管理人,Weston Nichols 是基金经理的普通合伙人唯一成员。每位申报人均否认拥有受益所有权,除非在任何金钱利益方面有相关利益。

Positive
  • None.
Negative
  • None.

Neuphoria Therapeutics Inc. (NEUP) ha ricevuto un report iniziale di proprietà su Modulo 3. La comunicazione elenca “Director” come relazione con l'emittente e indica che il modulo è stato presentato da più di una persona informante. La data dell'evento è 21/10/2025.

Il report mostra 236.218 azioni ordinarie di proprietà beneficiaria in modo indiretto, detenute da Lynx1 Master Fund LP. La presentazione spiega che Lynx1 Capital Management LP funge da gestore degli investimenti del fondo e Weston Nichols è l'unico socio accomandatario del gestore del fondo. Ciascun reporting person dichiara di non detenere proprietà beneficiaria salvo per l'eventuale interesse pecuniario.

Neuphoria Therapeutics Inc. (NEUP) recibió un informe inicial de propiedad en el Formulario 3. El registro indica “Director” como la relación con el emisor y señala que el formulario fue presentado por más de una persona informante. La fecha del evento es 21/10/2025.

El informe muestra 236,218 acciones ordinarias de propiedad beneficiaria en una base indirecta, mantenidas por Lynx1 Master Fund LP. La presentación explica que Lynx1 Capital Management LP actúa como administrador de inversiones del fondo y Weston Nichols es el único miembro del socio general del administrador del fondo. Cada persona informante rechaza la propiedad beneficiaria excepto en la medida de cualquier interés pecuniario.

Neuphoria Therapeutics Inc. (NEUP)는 Form 3에서 초기 소유권 보고를 받았습니다. 제출서는 발행자와의 관계를 “이사”로 기재하고 보고자가 둘 이상임을 나타냅니다. 이벤트 날짜는 2025년 10월 21일입니다.

보고서는 236,218주의 일반 주식간접적인 방식으로 유익하게 소유되었다고 표시되며, Lynx1 Master Fund LP가 보유합니다. 제출서는 Lynx1 Capital Management LP가 펀드의 투자관리자로 기능하며 Weston Nichols가 펀드 매니저의 일반 파트너의 유일한 구성원임을 설명합니다. 각 보고자는 금전적 이해관계의 범위에 한해만 유익한 소유권을 포기합니다.

Neuphoria Therapeutics Inc. (NEUP) a reçu un premier rapport de propriété sur le formulaire 3. Le dépôt indique « Directeur » comme relation avec l'émetteur et indique que le formulaire a été déposé par plus d'une personne déclarant. La date de l'événement est le 21/10/2025.

Le rapport indique 236 218 actions ordinaires détenues de manière indirecte par Lynx1 Master Fund LP. Le dépôt explique que Lynx1 Capital Management LP agit en tant que gestionnaire d'investissements du fonds et Weston Nichols est le seul membre du partenaire général du gestionnaire. Chaque personne déclarant décline la propriété bénéficiaire à l'exception de tout intérêt pécuniaire.

Neuphoria Therapeutics Inc. (NEUP) erhielt einen ersten Eigentumsnachweis auf Formular 3. Die Einreichung führt „Director“ als Beziehung zum Emittenten auf und gibt an, dass das Formular von mehr als einer meldepflichtigen Person eingereicht wurde. Das Ereignisdatum ist 2025-10-21.

Der Bericht zeigt 236.218 Stammaktien mit wohltuender Eigentümerschaft auf indirekter Basis, gehalten von Lynx1 Master Fund LP. Die Einreichung erklärt, dass Lynx1 Capital Management LP als Investmentmanager des Fonds fungiert und Weston Nichols der einzige Mitglied des General Partners des Fondsmanagers ist. Jede meldepflichtige Person lehnt die wirtschaftliche Eigentümerschaft ab, außer im Hinblick auf eventuelle finanzielle Interessen.

SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Lynx1 Capital Management LP

(Last) (First) (Middle)
D81 CALLE C, STE 301, PMB 1202

(Street)
DORADO PR 00646-2051

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
10/21/2025
3. Issuer Name and Ticker or Trading Symbol
Neuphoria Therapeutics Inc. [ NEUP ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common stock, $0.00001 par value per share 236,218 I See footnote(1)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
Lynx1 Capital Management LP

(Last) (First) (Middle)
D81 CALLE C, STE 301, PMB 1202

(Street)
DORADO PR 00646-2051

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Nichols Weston

(Last) (First) (Middle)
D81 CALLE C, STE 301, PMB 1202

(Street)
DORADO PR 00646-2051

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.
Lynx1 Capital Management LP, By: Lynx1 Capital Management GP LLC, its general partner, By: /s/ Weston Nichols, Sole Member 10/23/2025
/s/ Weston Nichols 10/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Neuphoria Therapeutics Inc

NASDAQ:NEUP

NEUP Rankings

NEUP Latest News

NEUP Latest SEC Filings

NEUP Stock Data

11.43M
2.16M
0.53%
67.79%
2.58%
Biotechnology
Pharmaceutical Preparations
Link
United States
BURLINGTON